Relationships between clinicopathological criteria, cytoplasmic IGFBP-3 and patient outcome

Variable	Univariate analysis		Multivariate analysis	
	95% CI	P	95% CI	P
Overall survival				
Age	0.99–1.04	0.4	0.98–2.90	**0.009**
Lymph node status (+/-)	2.79–153.9	**0.004**	2.65–161	**0.003**
Invasive tumour grade (I, II, III)	1.27–4.93	**0.002**	1.14–4.62	**0.002**
Tumour size	1.02–1.05	**<0.001**	1.02–1.05	**<0.001**
NPI	1.48–3.36	**<0.001**	1.39–3.32	**<0.001**
ER (quick-score)	0.66–0.92	**0.002**	0.68–0.98	**0.03**
HER-2 IHC score	0.94–2.02	**0.04**	0.76–1.95	0.56
Ki67 proliferative index	0.99–1.00	0.4	0.99–1.00	0.65
Lymphovascular invasion (+/-)	1.46–9.38	**0.006**	0.89–6.69	0.08
IGFBP-3 IHC score	0.62–2.01	0.719	0.59–2.50	0.592
Disease-free survival				
Age	0.97–1.02	0.9	0.99–1.06	0.06
Lymph node status (+/-)	2.29–25.3	**<0.001**	2.06–25.6	**0.002**
Invasive tumour grade (I, II, III)	1.48–5.38	**0.005**	1.36–5.11	**0.006**
Tumour size	1.02–1.04	**<0.001**	1.02–1.04	**<0.001**
NPI	1.46–3.17	**<0.001**	1.38–3.15	**<0.001**
ER (quick-score)	0.66–0.89	**0.001**	0.68–0.95	**0.01**
HER-2 IHC score	1.04–1.92	**0.02**	0.95–1.87	0.2
Ki67 proliferative index	0.99–1.00	0.2	0.99–1.00	0.3
Lymphovascular invasion (+/-)	1.63–6.95	**0.002**	1.09–6.65	**0.03**
IGFBP-3 IHC score	0.61–1.71	0.922	0.57–1.90	0.896

Confidence intervals (CI) and P values are given for the results of both the univariate and multivariate analyses. The multivariate analysis is adjusted for Nottingham Prognostic Index (NPI) (nodes, grade and size) and treatment (tamoxifen/chemotherapy/none). Data for univariate analysis were evaluable in 95 patients (reflecting the exclusion of six local tumour recurrences as described in the Methods section) and included